IP Library Granted Patent US 9,642,815
Granted Patent B2
US 9,642,815 · App. 15/033,513 · Granted May 9, 2017

Biocompatible graphene quantum dots for drug delivery and bioimaging applications

Inventors: Neetu Singh (Pune, IN); Anil Chandra (Pune, IN)
Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
A61K9/5146A61K49/0067B82Y5/00C01B31/0446C25B1/00C25F3/02G01N33/50B82Y15/00B82Y30/00B82Y40/00Y10S977/774Y10S977/788Y10S977/888Y10S977/90Y10S977/906Y10S977/927
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,642,815
App. No.
15/033,513
Granted
May 9, 2017
Kind
B2
Abstract

In this work we have targeted two aspects of GQDs, Size and ROS to reduce their cytotoxicity. Small size can damage cell organelles and production of ROS (reactive oxygen species) can hamper cell machinery in multiple ways. We have shown that cytotoxicity can be significantly reduced by embedding GQDs inside the PEG matrix rather than creating a thin shell around each GQD. Thin PEG shell around GQD can control ROS production but cannot circumvent the toxicity due to small size. Thus it was essential to solve both the issues. We have used a simple electrochemical method (12 h at room temperature) for synthesizing GQDs and embedded them in PEG matrix via a simple one step hydrothermal reaction (24 h at 160° C.) involving only GQDs, PEG, and deionized water. The P-GQDs formed after hydrothermal reaction show nanoparticles of diameter of ˜80-100 nm containing GQDs entrapped in PEG matrix. MTT assay showed significant 60% cells viability at a very high concentration of 5.5 mg/mL of P-GQDs compared to 10-15% viability for C-GQD and H-GQD. ROS production by P-GQDs was least compared to C-GQD and H-GQD in cell free and intracellular ROS assay suggesting involvement of ROS in cytotoxicity. In this work we have solved the issue of cytotoxicity due to ‘small size’ and ‘ROS generation’ without compromising with fluorescence properties of GQDs. P-GQDs was used for bioimaging and drug delivery in HeLa cells. In short we can obtain biocompatible P-GQDs in very short span of time with minimal use of hazardous chemicals and simple methodology.

Claims (8)

1. Biocompatible composition with reduced cytotoxicity comprising graphene quantum dots (GQDs) with a particle size ranging from 5-10 nm embedded in polyethylene glycol (PEG) matrix with a particle size ranging from 80-100 nm, for drug delivery and biomedical applications.

2. The biocompatible composition as claimed in claim 1 , wherein the composition of PEG-GQD at a concentrations of about 8 mg/mL shows up to 50% cell viability when tested on HeLa cell lines.

3. A process for preparation of biocompatible composition as claimed in claim 1 comprising the steps of:

i. electrochemical etching of multi walled carbon nanotubes at temperature in the range of 25°-28° C. for period in the range of 11 to 12 hrs to provide graphene quantum dots of size 5-10 nm;

ii. mixing graphene quantum dots as obtained in step (i) with polyethylene glycol followed by sonicating at temperature in the range of 20 to 35° C. for period in the range of 25 to 30 minutes to obtain a solution;

iii. autoclaving the solution as obtained in step (ii) at temperature in the range of 140°-180° C. for 23 to 24 hrs and;

iv. cooling at room temperature in the range of 20 to 35° C. followed by dialyzing to obtain biocompatible composition.

4. The process as claimed in claim 3 , wherein the concentration of GQDs embedded in polyethylene glycol is in the range of 1 mg/mL to 4 mg/mL.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2016
From: SINGH, NEETU; CHANDRA, ANIL
To: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
Reel/Frame 039817/0044 →
Priority Claims (1)
IN 3244/DEL/2013 · Nov 1, 2013 · national
Continuity (1)
Related Publication 20160256403A1 · Sep 8, 2016